Entero Healthcare Solutions will host an earnings call on August 10, 2026, at 12:00 PM IST to discuss its unaudited financial results for the quarter ended June 30, 2026. The announcement, filed with stock exchanges on August 4, 2026, invites analysts and investors to engage with the company's leadership regarding Q1FY27 performance metrics and operational updates.

The proceedings are conducted pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Sanu Kapoor, Vice President- Group General Counsel, Company Secretary & Compliance Officer, issued the intimation to the listing compliance departments of both BSE Limited and National Stock Exchange of India Limited. The discussions will be strictly based on publicly available information, with no forward-looking statements or non-public data expected to be shared.

Management Participation

The earnings call will feature key executives from Entero Healthcare Solutions who provide strategic oversight and financial guidance for the organization. The participating management members include:

These leaders will address queries regarding the company's quarterly performance, market positioning, and strategic initiatives undertaken during the period. Their presence ensures that investors receive direct insights into both operational execution and financial stewardship.

Event Logistics

Monarch Networth Capital serves as the organizer for the conference call, facilitating access for domestic and international participants. The event offers multiple dial-in options to ensure broad accessibility for stakeholders across different geographies.

Participants can also join via an Express Join link using a Diamond Pass. For RSVPs and further assistance, Mr. Rahul Dani at Monarch Networth Capital is the designated point of contact. The company noted that changes to the schedule or format may occur due to exigencies on the part of the host or the company.

Entero Healthcare Solutions Limited has released its Annual Report for the financial year 2025-26, alongside the Notice convening its 8th Annual General Meeting (AGM) scheduled for Wednesday, August 19, 2026, at 12:30 p.m. (IST), to be held through Video Conferencing (VC)/Other Audio Visual Means (OAVM). The filing was made with BSE Limited and National Stock Exchange of India Limited on July 27, 2026.

Key AGM Details

The following table summarises the schedule for the 8th AGM:

FY26 Financial Performance

FY26 marked a significant milestone in the company's evolution as an integrated healthcare supply chain platform. Consolidated revenue from operations grew 29.35% year-on-year to INR 65,912.12 million (FY25: INR 50,957.80 million), driven by 13.4% organic growth and 16% inorganic contribution. During the same period, the Indian Pharmaceutical Market grew by approximately 10%, reflecting continued market share gains by the company.

The following table presents the consolidated and standalone financial highlights for FY 2025-26:

Gross profit rose 39.91% year-on-year to INR 680.38 crore, with gross margins improving 78 basis points to 10.32%. EBITDA for the year stood at INR 265.96 crore, growing 55.03% year-on-year, with EBITDA margins improving 67 basis points to 4.03%. Profit After Tax (PAT) grew 35.75% to INR 145.84 crore (PAT margin: 2.21%), notwithstanding a one-time exceptional charge of INR 6.1 crore (net of tax) arising from the implementation of the new Labour Code.

Operating Cash Flow and Return Metrics

A notable highlight of FY26 was a meaningful improvement in operating cash flow, with OCF improving significantly from an outflow of INR 76.90 crore in FY25 to a net cash inflow from operations of approximately INR 96.20 crore in FY26, driven by better inventory management, tighter receivables control, and improved EBITDA margins.

Return metrics also strengthened considerably during the year:

Key Financial Ratios (Consolidated Basis)

The following table presents key financial ratios as disclosed in the Annual Report:

Operational Scale and Network

The company's platform as at FY26 serves over 105,300 retail pharmacy customers, 3,600+ hospital customers, and operates across 523 districts, supported by 136 warehouses and relationships with 3,300+ manufacturers. The portfolio spans 97,500+ SKUs handled. The company operates across 21 States & UTs with 6.29 lakh+ sq. ft. of warehousing space across 50 cities.

Strategic Acquisitions and MedTech Expansion

During FY26, the company completed seven strategic acquisitions across pharmaceutical distribution and the MedTech segment, contributing aggregate annualised revenue of over ₹1,000 crore. Three of these acquisitions were in the MedTech segment:

• Anand Chemiceutics Private Limited (51.51% stake) — leading IVD and MedTech distributor
• Ace Cardiopathy Solutions Private Limited (60% stake) — cardiovascular care MedTech distributor
• Bioaide Technologies Private Limited (80% stake) — focused on interventional cardiology, ENT, wound management, and neuropsychiatry

Additional acquisitions in pharmaceutical distribution included Ramson Medical Distributors Private Limited (70%), Sai RK Pharma Private Limited (70%), Well Wisher Pharma Private Limited (70%), and Anand Medilink Private Limited (80%). The MedTech vertical is expected to cross ₹1,000 crore in annualised revenue in FY27.

Dividend and Share Capital

The Board has not recommended any dividend for FY 2025-26 in order to conserve resources. During FY 2025-26, the paid-up equity share capital increased from Rs. 43,50,77,070/- to Rs. 43,51,09,370/-, pursuant to the allotment of 3,230 equity shares under the Entero Employees Stock Option Plan, 2023 (ESOP 2023). As on March 31, 2026, the company had 48 subsidiaries. India Ratings and Research affirmed the company's credit rating at 'IND A-' with a stable outlook during the year.

AGM Business and Director Appointments

The 8th AGM will consider ordinary business including adoption of audited financial statements for FY 2025-26 and re-appointment of Mr. Arun Sadhanandham (DIN: 08445197) as a Non-Executive Non-Independent Director, who retires by rotation. Special business includes approval of remuneration for Managing Director & CEO Mr. Prabhat Agrawal and Whole-time Director & COO Mr. Prem Sethi for their remaining tenures up to August 25, 2028, as well as re-appointment of Mr. Sujesh Vasudevan (DIN: 08240092) as Non-Executive Independent Director for a second term of 5 years (August 25, 2026 to August 24, 2031) and re-appointment of Ms. Sandhya Gadkari Sharma (DIN: 02005378) as Non-Executive Independent Director for a second term of 4 years (August 25, 2026 to August 24, 2030).

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE010601016/3df61e06d458431f.pdf